In stock · depth page
CJC-1295 with DAC — recent literature (RUO)
Long-acting GHRH analogue with Drug Affinity Complex
CJC-1295 with DAC 10 mg · literature note
For laboratory research use only. Not for human or veterinary use, consumption, compounding into a medicine, or injection. Not authorized by Health Canada. Literature on this page is scientific context only. This page is not a licensed drug, a wellness protocol, or a dosing guide. Not a licensed growth-hormone product in Canada.
No new primary GH/IGF-I efficacy trial for CJC-1295 with DAC was locked into this pack. The 2006 anchors stay. The recent rows are UHPLC-MS/MS and Orbitrap detection methods.
What recent means for this analogue
The 2006 core covers GH / IGF-I stimulation and pulsatility. The 2023–2026 index commonly returns detection methods that include CJC-1295 among GHRH analogues. Those methods are laboratory identity context.
No new primary GH/IGF-I efficacy trials for CJC-1295 with DAC indexed 2023–2026 are listed. Recent verified hits are analytical detection methods.
Identity
Form
Lyophilized powder, sealed vial
Strength
10 mg lyophilized vial
Purity
≥99% HPLC (see the lot COA)
CAS
- CJC-1295 with DAC: 446262-90-4
PubMed
Selected literature
- PMID 16352683 (2006) Teichman et al., Journal of Clinical Endocrinology & Metabolism — prolonged GH / IGF-I stimulation by CJC-1295
- PMID 17018654 (2006) Ionescu & Frohman, Journal of Clinical Endocrinology & Metabolism — GH pulsatility under continuous CJC-1295 stimulation
Recent literature (2023–2026)
- PMID 37806509 (2023) Cristea et al., Analytical Biochemistry — UHPLC-MS/MS detection of GHRHs in urine (includes CJC-1295)
- PMID 41138283 (2026) Uçaktürk & Nemutlu, Journal of Pharmaceutical and Biomedical Analysis — nano-LC-Q/Orbitrap MS of GHRH analogues including CJC-1295
Recent literature (2023–2026): No new primary GH/IGF-I efficacy trials for CJC-1295 with DAC indexed 2023–2026 are listed. Recent verified hits are analytical detection methods.
Literature is scientific context only. A paper does not make a research vial into a licensed medicine.
Bench reconstitution
Reconstitute from the parent brief: bacteriostatic water, solvent down the wall, swirl, do not shake. This page is the literature set.
Diluent page: bacteriostatic water.
Storage
Keep the lyophilized vial at 2–8 °C, protected from light and moisture, until the bench protocol calls for it. After reconstitution, hold at 2–8 °C; use within the sterility window your laboratory controls allow. Do not freeze–thaw repeatedly. Record open date and concentration in the notebook. Confirm the lot COA before you adopt a hold time.
Certificate of analysis
Every product has a View COA button. Where the lot certificate of analysis (identity and HPLC purity) is posted, it opens the certificate with a PDF download. Where it is not posted yet, the same button sends a request by email to request@pharmapeptidesrx.com, or you can write that address with the SKU. This page is not a COA.
Lab FAQ
Why are there no additional 2024–2026 efficacy PMIDs?
Because only PubMed-verified trials are listed. Write request@pharmapeptidesrx.com to add the 10 mg DAC vial to a research request. This page does not publish prices or banking details. Invoices go out from request@ only.
In this library
In stock · list price
Request from the catalog
Every vial on the catalog shows its CAD list price. Add it to your request and we email the invoice. Labs pay by Interac e-Transfer. No card checkout.